JP4354275B2 - 造血幹細胞およびその子孫の検出およびその使用 - Google Patents

造血幹細胞およびその子孫の検出およびその使用 Download PDF

Info

Publication number
JP4354275B2
JP4354275B2 JP2003540336A JP2003540336A JP4354275B2 JP 4354275 B2 JP4354275 B2 JP 4354275B2 JP 2003540336 A JP2003540336 A JP 2003540336A JP 2003540336 A JP2003540336 A JP 2003540336A JP 4354275 B2 JP4354275 B2 JP 4354275B2
Authority
JP
Japan
Prior art keywords
progeny
cells
hsc
fragment
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003540336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005506849A5 (https=
JP2005506849A (ja
Inventor
ニルソン，スーザン・ケイ
シモンズ，ポール・ジョン
ハイロック，デヴィッド・ノーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peter MacCallum Cancer Institute
Original Assignee
Peter MacCallum Cancer Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter MacCallum Cancer Institute filed Critical Peter MacCallum Cancer Institute
Publication of JP2005506849A publication Critical patent/JP2005506849A/ja
Publication of JP2005506849A5 publication Critical patent/JP2005506849A5/ja
Application granted granted Critical
Publication of JP4354275B2 publication Critical patent/JP4354275B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
JP2003540336A 2001-10-30 2002-10-24 造血幹細胞およびその子孫の検出およびその使用 Expired - Fee Related JP4354275B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8565A AUPR856501A0 (en) 2001-10-30 2001-10-30 Detection of haematopoietic stem cells and progeny and uses thereof
PCT/AU2002/001443 WO2003038071A1 (en) 2001-10-30 2002-10-24 Detection of haematopoietic stem cells and progeny and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009136863A Division JP2009232853A (ja) 2001-10-30 2009-06-08 造血幹細胞およびその子孫の検出およびその使用

Publications (3)

Publication Number Publication Date
JP2005506849A JP2005506849A (ja) 2005-03-10
JP2005506849A5 JP2005506849A5 (https=) 2005-12-22
JP4354275B2 true JP4354275B2 (ja) 2009-10-28

Family

ID=3832387

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003540336A Expired - Fee Related JP4354275B2 (ja) 2001-10-30 2002-10-24 造血幹細胞およびその子孫の検出およびその使用
JP2009136863A Pending JP2009232853A (ja) 2001-10-30 2009-06-08 造血幹細胞およびその子孫の検出およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009136863A Pending JP2009232853A (ja) 2001-10-30 2009-06-08 造血幹細胞およびその子孫の検出およびその使用

Country Status (7)

Country Link
US (3) US20050003460A1 (https=)
EP (1) EP1451303A4 (https=)
JP (2) JP4354275B2 (https=)
AU (2) AUPR856501A0 (https=)
CA (1) CA2464956A1 (https=)
IL (2) IL161690A0 (https=)
WO (1) WO2003038071A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030228635A1 (en) * 2002-02-15 2003-12-11 Renovar, Inc. Cell proliferation assays and methods
US20100145032A1 (en) * 2007-01-18 2010-06-10 Suomen Punainen Risti, Veripalelu Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
JP6057574B2 (ja) * 2012-07-11 2017-01-11 キヤノン株式会社 造血幹細胞識別用プローブ
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US20170318781A1 (en) * 2016-05-03 2017-11-09 Cattle Time, Llc Combined visual and rf identification (rfid) tag
JP7034949B2 (ja) 2016-05-25 2022-03-14 テルモ ビーシーティー、インコーポレーテッド 細胞の増殖
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
CN117247899A (zh) 2017-03-31 2023-12-19 泰尔茂比司特公司 细胞扩增
GB2619893A (en) 2021-03-23 2023-12-20 Terumo Bct Inc Cell capture and expansion
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875753B1 (en) * 1996-03-14 2005-04-05 The Governors Of The University Of Alberta Methods for cell mobilization using in vivo treatment with hyaluronan (HA)
EP1064011A1 (en) * 1998-03-13 2001-01-03 EntreMed, Inc. Metastatin and hyaluronate binding proteins and methods of use
WO2000017326A1 (en) 1998-09-21 2000-03-30 Musc Foundation For Research Development Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them
FR2789587B1 (fr) * 1999-02-11 2003-01-24 Inst Nat Sante Rech Med Moyens pour la regulation de la differenciation hematopoietique
US20030032621A1 (en) * 2000-02-11 2003-02-13 Florence Smadja-Joffe Means for regulating hematopoietic differentiation
WO2002044345A1 (en) * 2000-12-01 2002-06-06 The General Hospital Corporation Methods and products for manipulating hematopoietic stem cells

Also Published As

Publication number Publication date
CA2464956A1 (en) 2003-05-08
IL205407A0 (en) 2011-07-31
EP1451303A4 (en) 2006-03-08
IL161690A0 (en) 2004-09-27
US20080076148A1 (en) 2008-03-27
EP1451303A1 (en) 2004-09-01
AUPR856501A0 (en) 2001-11-29
JP2005506849A (ja) 2005-03-10
US20110020314A1 (en) 2011-01-27
JP2009232853A (ja) 2009-10-15
US20050003460A1 (en) 2005-01-06
US7718379B2 (en) 2010-05-18
WO2003038071A1 (en) 2003-05-08
AU2002335921B2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
JP2009232853A (ja) 造血幹細胞およびその子孫の検出およびその使用
JP4922548B2 (ja) 体性幹細胞の同定および単離ならびにその使用
Nilsson et al. Hyaluronan is synthesized by primitive hemopoietic cells, participates in their lodgment at the endosteum following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro
US10149864B2 (en) Method of isolating cells for therapy and prophylaxis
Sharpe III et al. The origin and in vivo significance of murine and human culture-expanded endothelial progenitor cells
Adamiak et al. Evidence for the involvement of sphingosine-1-phosphate in the homing and engraftment of hematopoietic stem cells to bone marrow
AU2002335921A1 (en) Detection of haematopoietic stem cells and progeny and uses thereof
Kim et al. Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease
CA2336490A1 (en) Hematopoietic cell composition for use in transplantation
US20240011988A1 (en) Cell preparation, use of protein in characterizing hematopoietic stem cells, and method for determining hematopoietic stem cells
Zhang et al. Recruitment of CD8+ T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1+ in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation
US20240272156A1 (en) Compositions and methods for identifying and isolating human hematopoietic stem and progenitor cells
Basu et al. Role of thrombomodulin expression on hematopoietic stem cells
JPWO2004005496A1 (ja) 臍帯血、骨髄、末梢血等に含まれる新規な未分化幹細胞集団
Zimmer Glycoprotein A repetition predominant (GARP) as a key molecule in the immunosuppressive tumor microenvironment
Pesce et al. UltraRapid Communication
Ahmed Homing and engraftment of CD34+ cells in the NOD/SCID model
Paderi Bone metabolism involvement in acute lymphocytic leukemia: the receptor Activator Nuclear Factor Kappa B Ligand pathway
Kim et al. Steven M. Garcia, Stanley Tamaki, Solomon Lee, Alvin Wong, Anthony Jose, Joanna Dreux, Gayle Kouklis, Hani Sbitany, Rahul Seth, 2 P. Daniel Knott, 2 Chase Heaton, 2 William R. Ryan, 2
Vercauteren et al. CD33 Expression is Absent on Primitive Acute Myeloid Leukemia Progenitors from Most Patients
Chu Enhanced engraftment of genetically modified bone marrow stromal cells
Tan Role of podocalyxin in hematopoiesis and cell migration
Liu CD44-high alveolar type II cells show stem cell properties during steady-state alveolar 1 homeostasis 2

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20081021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090427

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090630

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090729

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120807

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees